Osteros Biomedica presentation for Adam Smith Conference 2012

757 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
757
On SlideShare
0
From Embeds
0
Number of Embeds
171
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Osteros Biomedica presentation for Adam Smith Conference 2012

  1. 1. First in Class Delivery Treatmentfor Cancer-Induced Bone DiseasesAdam Smith ConferenceNovember 21-23, 2012
  2. 2. Cancer-Induced Bone Diseases Worldwide Incidence Incidence of Bone Metastasis • > 10,000,000 new cancer cases every year • 50% to 80% of carcinoma patients will have metastasis Prostate Myeloma in bone at the time of their 65-75% death 95-100% Lung 30-40% Current treatment • Conventional chemo- Breast Thyroid 60% therapeutics can not 65-75% accumulate in bone in relevant concentrations • Current therapies are only Renal 20-25% palliative Source: Coleman RE. Skeletal Complications of Malignancy. Cancer. 1997;80(suppl 8):1588-94.2
  3. 3. Problem and Solution Problem No Cure For Bone Metastasis Inability to deliver adequate amount of drug into the bone microenvironment Solution Bone targeting with drug release and accumulation in the bone microenvironment MBC-11 Compound etidronate-cytarabine Conjugate of a bisphosphonate with osteotropic properties and cytotoxic agent3
  4. 4. Bone delivery treatment Proven Bone Non-Toxic Proven Targeting Drug Linkage Drug (bisphosphonate) Therapeutic Bone binding via: payloads for: Potent Anti-resorptives  Multiple Myeloma  Osteosarcoma  Cancer metastasis Binds bone in Minutes Reduced Systemic Concentrates Therapy Toxicity at the Disease Localization • Unbound compound rapidly cleared due to Bone charge Reduced Risks • Linker is benign Releases Drug in Hours • Known Drugs phosphate • Known Effects4
  5. 5. IP development strategy IP current status US 6750340 Bisphosphonate conjugates and US 7598246 methods of making and using the СА 2443857 same EP 1383510 (GB, FR, DE) IP portfolio development Pre/Clinical research 2012 2013 2014 Improvement of the compound Clinical trial IP development Application for Improvement compound RUS PCT National phase Application for treatment RUS PCT National phase5
  6. 6. MBC-11 Efficacy in Rodent Models of Bone Diseases Multiple Myeloma – Treatment of bone disease  Increased bone mineral density  Increased survival rate Breast Cancer – Prevention of bone metastasis  Reduced incidence of bone metastasis up to 65%  Bone structure maintained Prostate Cancer – Treatment of bone metastasis and pain  Bone preservation  Reduced pain6
  7. 7. MBC-11 Efficacy in Spontaneous Canine Osteosarcoma Pilot study with 7 test subjects  Reduced tumor activity  Reduced pain  Reduced lameness  Improved quality of life Observations, events, outcome Day 0 6 14 28 85 110 SUV 23.61 24.57 21.28 16.76 N/A N/A7
  8. 8. Proof-of-Concept clinical trial • Proof-of-Concept clinical trial (Phase I/IIa ) in patients with metastatic bone disease (MBD) associated with late-stage cancers and relapsed / refractory multiple myeloma (RRMM) • 4 clinical centers • CT objective is to determine – safety – dose-limiting toxicities – maximum tolerated dose (MTD) – pharmacokinetics (PK) – preliminary efficacy8
  9. 9. Thank you for your attention Osteros Biomedica golub@osteros.ru +7 (495) 411-69-929

×